Projects per year
Personal profile
Biography
Professor Phil Darcy is currently a NHMRC Senior Research Fellow and Group Leader at the Peter MacCallum Cancer Centre. His laboratory focuses on developing novel T cell based immunotherapy approaches for cancer in preclinical mouse models and translating this into patients. Specifically, he is focused on the development of gene modified mouse and human T cells expressing chimeric antigen receptors (CARs) that can effectively target and eradicate cancer in mice. A Phase I clinical trial leading from this work was recently completed at the Peter MacCallum Cancer Centre in patients with acute myeloid leukaemia which represented a first in Australia using this approach and another trial using this approach in non-small cell lung carcinoma patients is underway. His laboratory is also focused on development of combined immune based therapies for cancer.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Cancer immunology
- T-cell
- Clinical translation
Collaborations and top research areas from the last five years
-
Developing novel CAR T cell therapy approaches to treat prostate cancer
Taylor, R. (Primary Chief Investigator (PCI)), Porter, L. (Chief Investigator (CI)), Trapani, J. (Associate Investigator (AI)), Darcy, P. (Associate Investigator (AI)), Neeson, P. J. (Associate Investigator (AI)), Risbridger, G. (Associate Investigator (AI)), Risbridger, G. (Associate Investigator (AI)), Solomon, B. J. (Associate Investigator (AI)), Azad, A. (Associate Investigator (AI)) & Furic, L. (Associate Investigator (AI))
1/01/22 → 31/12/25
Project: Research
-
Targeting Immune Checkpoints In Obesity-Driven HCC
Wiede, F. (Primary Chief Investigator (PCI)), Tiganis, T. (Associate Investigator (AI)), Darcy, P. (Associate Investigator (AI)), Johnstone, R. W. (Associate Investigator (AI)), McLean, C. (Associate Investigator (AI)) & Febbraio, M. (Associate Investigator (AI))
1/07/21 → 30/06/23
Project: Research
-
CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity
House, I. G., Derrick, E. B., Sek, K., Chen, A. X. Y., Li, J., Lai, J., Todd, K. L., Munoz, I., Michie, J., Chan, C. W., Huang, Y. K., Chan, J. D., Petley, E. V., Tong, J., Nguyen, D. M., Engel, S., Savas, P., Hogg, S. J., Vervoort, S. J. & Kearney, C. J. & 9 others, , 29 Aug 2023, In: Cell Reports. 42, 8, 27 p., 113014.Research output: Contribution to journal › Article › Research › peer-review
Open Access6 Citations (Scopus) -
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models
Porter, L. H., Zhu, J. J., Lister, N. L., Harrison, S. G., Keerthikumar, S., Goode, D. L., Urban, R. Q., Byrne, D. J., Azad, A., Vela, I., Hofman, M. S., Neeson, P. J., Darcy, P. K., Trapani, J. A., Taylor, R. A. & Risbridger, G. P., Dec 2023, In: Nature Communications. 14, 1, 17 p., 5346.Research output: Contribution to journal › Article › Research › peer-review
Open Access18 Citations (Scopus) -
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity
Wiede, F., Lu, K.-H., Du, X., Zeissig, M. N., Xu, R., Goh, P. K., Xirouchaki, C. E., Hogarth, S. J., Greatorex, S., Sek, K., Daly, R. J., Beavis, P. A., Darcy, P. K., Tonks, N. K. & Tiganis, T., 1 Mar 2022, In: Cancer Discovery. 12, 3, p. 752-773 22 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access85 Citations (Scopus) -
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes
Trigos, A. S., Pasam, A., Banks, P., Wallace, R., Guo, C., Keam, S., Thorne, H., Mitchell, C., Lade, S., Clouston, D., Hakansson, A., Liu, Y., Blyth, B., Murphy, D., Lawrentschuk, N., Bolton, D., Moon, D., Darcy, P., Haupt, Y. & Williams, S. G. & 5 others, , Jun 2022, In: Journal for ImmunoTherapy of Cancer. 10, 6, 12 p., e003744.Research output: Contribution to journal › Article › Research › peer-review
Open Access11 Citations (Scopus) -
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Giuffrida, L., Sek, K., Henderson, M. A., Lai, J., Chen, A. X. Y., Meyran, D., Todd, K. L., Petley, E. V., Mardiana, S., Mølck, C., Stewart, G. D., Solomon, B. J., Parish, I. A., Neeson, P. J., Harrison, S. J., Kats, L. M., House, I. G., Darcy, P. K. & Beavis, P. A., Dec 2021, In: Nature Communications. 12, 1, 18 p., 3236.Research output: Contribution to journal › Article › Research › peer-review
Open Access136 Citations (Scopus)